Abstract:Objective: To investigate the clinical efficacy of methylprednisolone in the treatment of children with intractable pneumonia mycoplasma pneumonia. Methods: 200 infants with refractory mycoplasma pneumoniae pneumonia admitted from January 2016 to October 2017 were randomly divided into two groups, the control group received azithromycin, and the observation group received methylprednisolone Group of children with clinical indicators, the overall effect of treatment, disease-related parameters and safety. Results: The cough onset time, cough disappearance time, antipyretic time, wet rales disappear time, wheezing disappearance time and hospitalization time in observation group were significantly lower than those in control group. The 2/3 shadow absorption rate Significantly higher than the control group; the total effective rate was significantly higher than the control group; after treatment, the white blood cell count was significantly higher than the control group, CRP, IL-4, IL-10, IL-17 and TGF- Significantly lower than the control group, there was a significant difference (P <0.05); two groups of children with adverse drug reaction rate was not significantly different (P> 0.05). Conclusion: The clinical efficacy of methylprednisolone in the treatment of pediatric intractable pneumonia mycoplasma pneumonia is significant and has reference value.